Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for rivaroxaban (Xarelto) for the treatment of venous thromboembolic events (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children and adolescents aged less than 18 years after at least 5 days of initial parenteral anticoagulation treatment.